Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 versus SAVAYSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 versus SAVAYSA.
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% vs SAVAYSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing clot formation and extension.
Direct inhibitor of factor Xa, thereby decreasing thrombin generation and fibrin clot formation.
IV continuous infusion: initial bolus 80 units/kg, then maintenance 18 units/kg/hour; titrate to aPTT 1.5-2.5 times control. The solution HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% is typically used for continuous infusion; dose should be adjusted based on patient weight and aPTT.
5 mg orally twice daily for nonvalvular atrial fibrillation; 5 mg orally twice daily for venous thromboembolism treatment after initial parenteral anticoagulation for 5-10 days.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours (mean 1.6 h) at therapeutic doses, but is dose-dependent: 30-60 min after 25 U/kg, 1-2 h after 100-200 U/kg, and 2.5-5 h after 400-800 U/kg. Half-life is prolonged in hepatic or renal impairment.
Terminal elimination half-life is 10-14 hours; in healthy subjects, mean half-life is approximately 10 hours. Clinically, this supports once-daily dosing. Half-life is prolonged in renal impairment (e.g., up to 17 hours in severe renal impairment).
Heparin is eliminated primarily via the reticuloendothelial system and renal excretion. Approximately 50% is excreted unchanged in urine via saturable zero-order kinetics, with the remainder metabolized to uroheparin and other inactive metabolites. Biliary/fecal excretion is negligible (<5%).
Eliminated primarily via renal excretion of unchanged drug (approximately 82% of an oral dose is excreted in urine as edoxaban). Fecal/biliary excretion accounts for about 8%. Minor metabolism (<10%) via hydrolysis (mediated by carboxylesterase 1) and conjugation, with metabolites excreted renally or in feces.
Category A/B
Category C
Anticoagulant
Anticoagulant, Direct Factor Xa Inhibitor